NEW Rapid FISH Hybridizer

CytoBrite Slide Incubation System for performing FISH/ISH hybridization protocols.

By | June 16, 2014

Request More Information

SciGene (Sunnyvale, CA) today introduced the CytoBrite Slide Incubation System, a new programmable system for performing FISH/ISH hybridization protocols on 1 to 12 slides using Peltier technology for rapid heating and cooling. The CytoBrite System accurately detects true slide conditions using SlideSense™ technology and records times and temperatures to a USB file. Removable trays transfer slides during probe addition, coverslipping and instrument loading to reduce handling. The system uses CytoBond Removable Coverslip Sealant to eliminate the need for humidification.

About SciGene
SciGene (Sunnyvale, California, USA) is a privately held company, founded in 2003, that develops instruments and reagents to automate FISH and CMA workflows used in research and clinical diagnostic laboratories.

Request More Information

Product Details

SciGene Corporation CytoBrite Slide Incubation System

image of: SciGene Corporation CytoBrite Slide Incubation System

Programmable slide incubation system for performing FISH/ISH hybridization protocols on 1 to 12 slides.

Depth38cm
Height20cm
Incubator OrientationBenchtop
Weight9kg
Width25cm

Request More Information

Your Request
About You
Enter text from the image above:

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham